Phathom Pharmaceuticals (PHAT) has released an update.
Phathom Pharmaceuticals, Inc. has made strides in the healthcare market as their drug VOQUEZNA gains immediate inclusion on Express Scripts’ national formularies for commercial plans. This significant development simplifies patient access to VOQUEZNA by allowing it to be prescribed directly after a generic proton pump inhibitor, streamlining treatment options for those in need.
For further insights into PHAT stock, check out TipRanks’ Stock Analysis page.
